Letter in HemaSphere

Together with clinical partners from the University Hospital Erlangen, Thomas Zerjatke and Prof. Ingmar Glauche published a letter in HemaSphere about switching children and adolescents with chronic myeloid leukemia (CML) from the first-line treatment, imatinib, to second-generation tyrosine kinase inhibitors (2G-TKIs). The study showed that switching treatments improved molecular response in a specific group of patients, helping them achieve remission faster. These results highlight the need for personalized treatment plans to improve outcomes and reduce long-term side effects, especially in young patients.

Letter in HemaSphere:https://onlinelibrary.wiley.com/doi/10.1002/hem3.70347